News & Events » News » RBM Partnership to End Malaria welcomes approval for single-dose Krintafel (tafenoquine) in the United States

RBM Partnership to End Malaria welcomes approval for single-dose Krintafel (tafenoquine) in the United States

Geneva, 23 July 2018 — The RBM Partnership to End Malaria welcomes the United States Food and Drug Administration (FDA) approval of Krintafel (tafenoquine), a major breakthrough for treating the P. Vivax strain of malaria, which causes relapses of the debilitating disease even in the absence of a new mosquito bite.

The RBM Partnership congratulates its long-standing partners, including GlaxoSmithKline, the Medicines for Malaria Venture (MMV), and Bill & Melinda Gates Foundation on this achievement, and looks forward to working with these and other partners, especially in regions most affected by the P. Vivax strain of malaria, to maximise the benefits of this new treatment.

With an estimated 8.5 million clinical infections every year, including more than half of all malaria cases in the Americas and one-third in South-East Asia, this new drug can make a significant contribution to the attainment of the World Health Organization (WHO)’s global malaria elimination targets.

Dr David Reddy, MMV Chief Executive and Board member of the RBM Partnership, said: “The US FDA’s approval of Krintafel is a major milestone and a significant contribution towards global efforts to eradicate malaria. The world has waited decades for a new medicine to counter P. vivax malaria relapse. Today, we can say the wait is over. Moreover, as the first ever single-dose for this indication, Krintafel will help improve patient compliance. We are proud to have worked side-by-side with GSK for more than a decade to reach this point. Our focus is now on working to ensure the medicine reaches the vulnerable patients that need it most.”

Dr Kesete Admasu, CEO of the RBM Partnership to End Malaria, comments; “This is a fantastic achievement for all those fighting malaria. Milestones such as this underline the importance of consistent funding and targeting of efforts in developing innovations and treatments – after all malaria as a disease continues to evolve so it is essential that we stay ahead of the curve, and develop and deploy new effective treatments as quickly as possible.”

Encouraging research and development for new innovations and treatments for malaria is a priority for the RBM Partnership. Developments such as this offer an opportunity to take great strides in the fight against malaria, reaching large populations affected by the disease and saving lives. Importantly, new and innovative malaria treatments such as Krintafel can help prevent further spread and transmission of the disease within these communities, add momentum to countries’ own efforts to reach malaria elimination status, and achieve additional social and economic benefits.

Geneva, 23 July 2018 — The RBM Partnership to End Malaria welcomes the United States Food and Drug Administration (FDA) approval of Krintafel (tafenoquine), a major breakthrough for treating the P. Vivax strain of malaria, which causes relapses of the debilitating disease even in the absence of a new mosquito bite.

The RBM Partnership congratulates its long-standing partners, including GlaxoSmithKline, the Medicines for Malaria Venture (MMV), and Bill & Melinda Gates Foundation on this achievement, and looks forward to working with these and other partners, especially in regions most affected by the P. Vivax strain of malaria, to maximise the benefits of this new treatment.

With an estimated 8.5 million clinical infections every year, including more than half of all malaria cases in the Americas and one-third in South-East Asia, this new drug can make a significant contribution to the attainment of the World Health Organization (WHO)’s global malaria elimination targets.

Dr David Reddy, MMV Chief Executive and Board member of the RBM Partnership, said: “The US FDA’s approval of Krintafel is a major milestone and a significant contribution towards global efforts to eradicate malaria. The world has waited decades for a new medicine to counter P. vivax malaria relapse. Today, we can say the wait is over. Moreover, as the first ever single-dose for this indication, Krintafel will help improve patient compliance. We are proud to have worked side-by-side with GSK for more than a decade to reach this point. Our focus is now on working to ensure the medicine reaches the vulnerable patients that need it most.”

Dr Kesete Admasu, CEO of the RBM Partnership to End Malaria, comments; “This is a fantastic achievement for all those fighting malaria. Milestones such as this underline the importance of consistent funding and targeting of efforts in developing innovations and treatments – after all malaria as a disease continues to evolve so it is essential that we stay ahead of the curve, and develop and deploy new effective treatments as quickly as possible.”

Encouraging research and development for new innovations and treatments for malaria is a priority for the RBM Partnership. Developments such as this offer an opportunity to take great strides in the fight against malaria, reaching large populations affected by the disease and saving lives. Importantly, new and innovative malaria treatments such as Krintafel can help prevent further spread and transmission of the disease within these communities, add momentum to countries’ own efforts to reach malaria elimination status, and achieve additional social and economic benefits.

Latest News

29.11.18
The RBM working groups for vector control, case management, malaria in pregnancy and multi-sectoral... Read more.
27.11.18
On 19 November 2018, the RBM Partnership to End Malaria celebrated its 20th anniversary in Maputo,... Read more.
19.11.18
Maputo, 19 November 2018 – The RBM Partnership to End Malaria today calls on countries to step up... Read more.
08.11.18
Following the Eastern and Southern Africa Sub-Regional Network (ESASRN) Meeting in Addis Ababa (8-... Read more.